HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now
Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drug\xe2\x80\x99s efficacy.\nBut the truth began to emerge on Mar.
- Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drug\xe2\x80\x99s efficacy.\nBut the truth began to emerge on Mar.
- 8, 2021, when Acadia announced that on Mar.
- 3, 2021 the FDA informed the company that it had identified deficiencies in the sNDA.\nThen, on Apr.
- Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.